Racura Oncology Ltd (ASX:RAC)

Australia flag Australia · Delayed Price · Currency is AUD
2.410
-0.060 (-2.43%)
At close: Mar 2, 2026
102.52%
Market Cap 448.80M
Revenue (ttm) 3.48M
Net Income (ttm) -9.39M
Shares Out 181.70M
EPS (ttm) -0.05
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 141,614
Average Volume 133,299
Open 2.420
Previous Close 2.470
Day's Range 2.320 - 2.430
52-Week Range 0.920 - 4.900
Beta 0.91
RSI 54.92
Earnings Date Feb 25, 2026

About Racura Oncology

Racura Oncology Ltd operates as a Phase 3 clinical biopharmaceutical company for cancer care. Its lead asset is RCDS1 (E,E-bisantrene), a small molecule anticancer agent that primarily functions through G4-DNA & RNA binding to potent inhibition of the cancer growth regulator MYC. The company is advancing a proprietary formulation of RCDS1 (RC220) to address the unmet needs of patients across various oncology indications with Phase 3 clinical programs in acute myeloid leukaemia, Phase 1a/b program in mutant epidermal growth factor receptor non-s... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2011
Country Australia
Stock Exchange Australian Securities Exchange
Ticker Symbol RAC
Full Company Profile

Financial Performance

In fiscal year 2025, Racura Oncology's revenue was 6.04 million, an increase of 24.96% compared to the previous year's 4.84 million. Losses were -4.79 million, -65.36% less than in 2024.

Financial Statements

News

There is no news available yet.